BSD Medical Delivers BSD-2000 Hyperthermia System to Cancer Treatment Centers of America® in Arizona

  BSD Medical Delivers BSD-2000 Hyperthermia System to Cancer Treatment
  Centers of America® in Arizona

Business Wire

SALT LAKE CITY -- June 5, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (, a
leading provider of medical systems that utilize targeted heat therapy to
treat cancer, announced today that it has delivered a BSD-2000 Hyperthermia
System (BSD-2000) to Cancer Treatment Centers of America^® (CTCA) at Western
Regional Medical Center (WRMC), located in Goodyear, Ariz. WRMC serves the
western United States, including the major metropolitan areas of Phoenix,
Denver, Los Angeles, Las Vegas, Seattle, Portland and Albuquerque. This is the
eighth BSD Hyperthermia system purchased by CTCA^®.

WRMC is a state-of-the-art, all-digital cancer hospital that provides advanced
cancer treatments, world-class technologies and integrative therapies under
one roof. The 213,000-square-foot facility is located on a 25-acre site, which
is part of the Phoenix metropolitan area. Like the other CTCA cancer
hospitals, WRMC provides the most advanced therapeutic resources in cancer

CTCA is a network of hospitals and one of the premier providers of cancer care
in the world. CTCA physicians specialize in treating many types of cancer,
including complex and advanced stage cases. “As the Medical Director of the
Department of Radiation Oncology at the Cancer Treatment Centers of America in
suburban Phoenix, Ariz., I am absolutely excited to be able to evolve our
cancer therapeutics and research sophistication and capabilities with the
advent of deep tissue hyperthermia,” said Dr. Lanceford M. Chong. “Our robust
and multidisciplinary clinical protocols will allow us to partner with other
academic institutions as we, together, evolve patient care and further
oncologic knowledge, as well as explore the next frontier of cancer medicine
in our unified and determined quest to conquer cancer!”

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia), while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at

About Cancer Treatment Centers of America®

Cancer Treatment Centers of America, Inc. (CTCA) is a national network of
hospitals focusing on complex and advanced stage cancer. CTCA offers a
comprehensive, fully integrated approach to cancer treatment and serves
patients from all 50 states at facilities located in Atlanta, Chicago,
Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of
care and Patient Empowerment Medicine®, CTCA provides patients with
information about cancer and their treatment options so they can control their
treatment decisions. For more information about CTCA, go to

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.


BSD Medical Corporation
William (Bill) Barth, 801-972-5555
fax: 801-972-5930
Press spacebar to pause and continue. Press esc to stop.